A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
Latest Information Update: 01 Oct 2022
At a glance
- Drugs Lenalidomide (Primary) ; Luspatercept (Primary)
- Indications Anaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 10 Nov 2021 Planned End Date changed from 1 Aug 2028 to 1 Aug 2029.
- 10 Nov 2021 Planned primary completion date changed from 1 Aug 2028 to 1 Aug 2029.
- 10 Nov 2021 Status changed from not yet recruiting to recruiting.